

CorMedix Inc.  
Form 8-K  
March 19, 2012

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): March 19, 2012

CORMEDIX INC.

(Exact Name of Registrant as Specified in Charter)

Delaware                              001-34673      20-5894890  
(State or Other Jurisdiction (Commission (IRS Employer  
of Incorporation)                      File Number) Identification No.)

745 Rt. 202-206, Suite 303, Bridgewater, 08807  
NJ  
(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Edgar Filing: CorMedix Inc. - Form 8-K

- “ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On March 19, 2012, CorMedix Inc., a Delaware corporation (the “Company”) issued a press release reporting year end 2011 financial results. The full text of the Company’s press release is attached to this Current Report on Form 8-K as Exhibit 99.1.\*

**Item 9.01 Financial Statements and Exhibits.**

(d)

*Exhibits*

Exhibit No. Description

99.1 Press Release of CorMedix Inc., dated March 19, 2012.

\* The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 19, 2012 CORMEDIX INC.

By: /s/ Brian Lenz

Name: Brian Lenz

Title: Chief Operating Officer and Chief Financial Officer

**EXHIBIT INDEX**

Exhibit No. Description

99.1 Press Release of CorMedix Inc., dated March 19, 2012.